Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Sell
31
IQV Quote, Financials, Valuation and Earnings
Last price:
$140.19
Seasonality move
:
10.61%
Day range:
$137.33 - $141.33
52-week range:
$134.65 - $252.88
Dividend yield:
0%
P/E ratio:
19.12x
P/S ratio:
1.64x
P/B ratio:
4.06x
Volume:
2.9M
Avg. volume:
2.5M
1-year change:
-36.92%
Market cap:
$24.3B
Revenue:
$15.4B
EPS (TTM):
$7.34
Analysts' Opinion
-
Consensus RatingIQVIA Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $190.62, IQVIA Holdings has an estimated upside of 35.84% from its current price of $140.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $160.00 representing 100% downside risk from its current price of $140.33.
Fair Value
-
According to the consensus of 21 analysts, IQVIA Holdings has 35.84% upside to fair value with a price target of $190.62 per share.
IQV vs. S&P 500
-
Over the past 5 trading days, IQVIA Holdings has underperformed the S&P 500 by -0.21% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
IQVIA Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IQVIA Holdings has grown year-over-year revenues for 19 quarters straight. In the most recent quarter IQVIA Holdings reported revenues of $3.8B.
Earnings Growth
-
IQVIA Holdings earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter IQVIA Holdings reported earnings per share of $1.40.
Enterprise value:
36.7B
EV / Invested capital:
--
Price / LTM sales:
1.64x
EV / EBIT:
15.83x
EV / Revenue:
2.37x
PEG ratio (5yr expected):
69.97x
EV / Free cash flow:
16.99x
Price / Operating cash flow:
11.79x
Enterprise value / EBITDA:
10.69x
Gross Profit (TTM):
$5.4B
Return On Assets:
4.96%
Net Income Margin (TTM):
8.61%
Return On Equity:
20.79%
Return On Invested Capital:
6.62%
Operating Margin:
13.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $14.5B | $15.1B | $15.5B | $3.7B | $3.8B | |
| Gross Profit | $5B | $5.3B | $5.4B | $1.3B | $1.3B | |
| Operating Income | $1.8B | $2.1B | $2.3B | $521M | $525M | |
| EBITDA | $2.9B | $3.3B | $3.4B | $770M | $753M | |
| Diluted EPS | $5.56 | $7.32 | $7.34 | $1.56 | $1.40 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.6B | $4.8B | $5.3B | $5.7B | $5.9B | |
| Total Assets | $24.5B | $25B | $25.7B | $26.6B | $27.3B | |
| Current Liabilities | $4.9B | $5.2B | $6.7B | $6.4B | $7.2B | |
| Total Liabilities | $18.2B | $19.1B | $19.8B | $20.2B | $21.3B | |
| Total Equity | $6.2B | $5.9B | $5.9B | $6.3B | $6B | |
| Total Debt | $12.2B | $12.6B | $13.2B | $13.5B | $14.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.2B | $2.3B | $2.8B | $522M | $568M | |
| Cash From Investing | -$1.6B | -$1.7B | -$1.4B | -$314M | -$305M | |
| Cash From Financing | -$386M | -$575M | -$1B | -$106M | -$258M | |
| Free Cash Flow | $1.5B | $1.6B | $2.2B | $377M | $426M | |
IQV
Sector
Market Cap
$24.3B
$33.4M
Price % of 52-Week High
55.49%
45.25%
Dividend Yield
0%
0%
Shareholder Yield
5.19%
-0.66%
1-Year Price Total Return
-36.92%
-40%
Beta (5-Year)
1.344
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$139.74
200-day SMA
Sell
Level
$198.56
Bollinger Bands (100)
Sell
Level
151.03 - 199.05
Chaikin Money Flow
Buy
Level
135.7M
20-day SMA
Sell
Level
$145.05
Relative Strength Index (RSI14)
Sell
Level
42.37
ADX Line
Sell
Level
35.32
Williams %R
Neutral
Level
-74.0233
50-day SMA
Sell
Level
$153.96
MACD (12, 26)
Sell
Level
-4.34
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
26.5M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.1217)
Sell
CA Score
(Annual)
Level (-1.0981)
Buy
Beneish M-Score
(Annual)
Level (-2.7641)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.757)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Stock Forecast FAQ
In the current month, IQV has received 14 Buy ratings 7 Hold ratings, and 0 Sell ratings. The IQV average analyst price target in the past 3 months is $190.62.
-
Where Will IQVIA Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that IQVIA Holdings share price will rise to $190.62 per share over the next 12 months.
-
What Do Analysts Say About IQVIA Holdings?
Analysts are divided on their view about IQVIA Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IQVIA Holdings is a Sell and believe this share price will drop from its current level to $160.00.
-
What Is IQVIA Holdings's Price Target?
The price target for IQVIA Holdings over the next 1-year time period is forecast to be $190.62 according to 21 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is IQV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IQVIA Holdings is a Buy. 14 of 21 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IQV?
You can purchase shares of IQVIA Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IQVIA Holdings shares.
-
What Is The IQVIA Holdings Share Price Today?
IQVIA Holdings was last trading at $140.19 per share. This represents the most recent stock quote for IQVIA Holdings. Yesterday, IQVIA Holdings closed at $140.33 per share.
-
How To Buy IQVIA Holdings Stock Online?
In order to purchase IQVIA Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
